Mitera Biosciences

At Mitera Biosciences we are focused on the promising field of Regulatory T cell (“Treg”) biology. Tregs are a key component in maintaining a healthy and balanced innate immune system. Transplant recipients and autoimmune disease patients suffer from a deficiency of Tregs, hence the urgent need to find ways to enhance the number of these cells circulating in the body. Leveraging intellectual property exclusively licensed from world renowned Cedars Sinai Medical Center (Los Angeles, California), our drug candidates are derived from a natural human protein which is produced by the human placenta during pregnancy and is also abundantly expressed in the thymus. Recent data suggest this protein may be an important regulator of maternal-fetal tolerance during pregnancy. Since this protein can up regulate regulatory T-cells (Tregs) and impair T effector (Teff) cells, we felt it would be an important agent to investigate as a potential therapeutic for prevention of transplant rejection and a treatment for autoimmune diseases, conditions which are known to be perpetuated by Teff and suppressed by Treg cells. If successful in future clinical studies, our therapeutic drug candidates could help patients in need without the toxicity of today’s mainstay immunosuppressant drugs such as calcineurin inhibitors and mycophenolic acid. We are also exploring this novel axis of immunobiology for the development of additional therapeutic drug programs.